Artiva Biotherapeutics (NASDAQ:ARTV) Rating Lowered to Sell at Wall Street Zen

Artiva Biotherapeutics (NASDAQ:ARTV) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.

ARTV has been the topic of a number of other research reports. Wedbush downgraded Artiva Biotherapeutics from an “outperform” rating to a “neutral” rating and set a $4.00 target price on the stock. in a research note on Tuesday, October 27th. Jefferies Financial Group cut Artiva Biotherapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research note on Thursday. HC Wainwright reissued a “buy” rating on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Monday, October 19th. Finally, TD Cowen downgraded shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $24.80.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $4.19 on Friday. Artiva Biotherapeutics has a 52-week low of $2.96 and a 52-week high of $14.53. The stock has a market cap of $204.85 million, a P/E ratio of -1.27 and a beta of 2.68. The firm has a 50 day moving average price of $8.11 and a two-hundred day moving average price of $7.96.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). Analysts predict that Artiva Biotherapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity at Artiva Biotherapeutics

In other news, COO Jennifer Bush sold 8,370 shares of Artiva Biotherapeutics stock in a transaction on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $57,250.80. Following the completion of the sale, the chief operating officer directly owned 366,159 shares of the company’s stock, valued at approximately $2,504,527.56. The trade was a 2.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Subhashis Banerjee sold 8,222 shares of the firm’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.01, for a total value of $98,746.22. Following the completion of the sale, the insider directly owned 142,047 shares of the company’s stock, valued at approximately $1,705,984.47. This trade represents a 5.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 137,048 shares of company stock valued at $1,086,167. 1.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. 5AM Venture Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $22,827,049. Blue Owl Capital Holdings LP bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth $8,483,000. BlackRock Inc. bought a new stake in Artiva Biotherapeutics during the second quarter worth about $6,739,000. Nantahala Capital Management LLC bought a new stake in Artiva Biotherapeutics in the second quarter valued at $2,910,000. Finally, Alyeska Investment Group L.P. raised its position in Artiva Biotherapeutics by 173.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after buying an additional 173,615 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.